Skip to content

Study · Animal study (in vivo) · mouse · 2010

4 results

Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse.

Spurney CF, Cha HJ, Sali A, Pandey GS, Pistilli E, Guerron AD, Gordish-Dressman H, Hoffman EP, Nagaraju K

PloS one29 Jan 2010Cited by 25 (Europe PMC)

PMID20126456 (opens in a new tab)PMCIDPMC2813286 (opens in a new tab)DOI10.1371/journal.pone.0008976 (opens in a new tab)PepBankPUB-20126456
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Thymosin beta-4 (Tbeta4) is a ubiquitous protein with many properties relating to cell proliferation and differentiation that promotes wound healing and modulates inflammatory mediators. We studied the effects of chronic administration of Tbeta4 on the skeletal and cardiac muscle of dystrophin deficient mdx mice, the mouse model of Duchenne muscular dystrophy. Female wild type (C57BL10/ScSnJ) and mdx mice, 8-10 weeks old, were treated with 150 microg of Tbeta4 twice a week for 6 months. To promote muscle pathology, mice were exercised for 30 minutes twice a week. Skeletal and cardiac muscle function were assessed via grip strength and high frequency echocardiography. Localization of Tbeta4 and amount of fibrosis were quantified using immunohistochemistry and Gomori's tri-chrome staining, respectively. Mdx mice treated with Tbeta4 showed a significant increase in skeletal muscle regenerating fibers compared to untreated mdx mice. Tbeta4 stained exclusively in the regenerating fibers of mdx mice. Although untreated mdx mice had significantly decreased skeletal muscle strength compared to untreated wild type, there were no significant improvements in mdx mice after treatment. Systolic cardiac function, measured as percent shortening fraction, was decreased in untreated mdx mice compared to untreated wild type and there was no significant difference after treatment in mdx mice. Skeletal and cardiac muscle fibrosis were also significantly increased in untreated mdx mice compared to wild type, but there was no significant improvement in treated mdx mice. In exercised dystrophin deficient mice, chronic administration of Tbeta4 increased the number of regenerating fibers in skeletal muscle and could have a potential role in treatment of skeletal muscle disease in Duchenne muscular dystrophy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In exercised mdx mice, chronic Tbeta4 increased the number of regenerating skeletal muscle fibers compared with untreated mdx mice.

    In plain wordsIn mdx mice, long-term thymosin beta‑4 increased regenerating muscle fibers compared with untreated mdx mice.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseSkeletal muscle regenerating fibers
    Study

    mousen: not reported in source

    mdx mouse (Duchenne muscular dystrophy model), exercised
    Comparator
    Untreated mdx mice
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    150 microg twice a week · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Mdx mice treated with Tbeta4 showed a significant increase in skeletal muscle regenerating fibers compared to untreated mdx mice.
    2 context sentences
    Summary · context
    Female wild type (C57BL10/ScSnJ) and mdx mice, 8-10 weeks old, were treated with 150 microg of Tbeta4 twice a week for 6 months.
    Summary · context
    To promote muscle pathology, mice were exercised for 30 minutes twice a week.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In exercised mdx mice, Tbeta4 did not significantly improve skeletal muscle strength.

    In plain wordsIn mdx mice, thymosin beta‑4 did not significantly improve muscle strength.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeSkeletal muscle strength (grip strength)
    Study

    mousen: not reported in source

    mdx mouse (Duchenne muscular dystrophy model), exercised
    Comparator
    Untreated mdx mice
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    150 microg twice a week · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Although untreated mdx mice had significantly decreased skeletal muscle strength compared to untreated wild type, there were no significant improvements in mdx mice after treatment.
    2 context sentences
    Summary · context
    Female wild type (C57BL10/ScSnJ) and mdx mice, 8-10 weeks old, were treated with 150 microg of Tbeta4 twice a week for 6 months.
    Summary · context
    To promote muscle pathology, mice were exercised for 30 minutes twice a week.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mdx mice, Tbeta4 treatment produced no significant difference in systolic cardiac function.

    In plain wordsIn mdx mice, thymosin beta‑4 did not significantly change heart pumping function.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeSystolic cardiac function (percent shortening fraction)
    Study

    mousen: not reported in source

    mdx mouse (Duchenne muscular dystrophy model), exercised
    Comparator
    Untreated mdx mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    150 microg twice a week · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Systolic cardiac function, measured as percent shortening fraction, was decreased in untreated mdx mice compared to untreated wild type and there was no significant difference after treatment in mdx mice.
    2 context sentences
    Summary · context
    Female wild type (C57BL10/ScSnJ) and mdx mice, 8-10 weeks old, were treated with 150 microg of Tbeta4 twice a week for 6 months.
    Summary · context
    To promote muscle pathology, mice were exercised for 30 minutes twice a week.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mdx mice, Tbeta4 treatment produced no significant improvement in skeletal or cardiac muscle fibrosis.

    In plain wordsIn mdx mice, thymosin beta‑4 did not significantly reduce scarring in skeletal or heart muscle.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeSkeletal and cardiac muscle fibrosis
    Study

    mousen: not reported in source

    mdx mouse (Duchenne muscular dystrophy model), exercised
    Comparator
    Untreated mdx mice
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    150 microg twice a week · 6 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Skeletal and cardiac muscle fibrosis were also significantly increased in untreated mdx mice compared to wild type, but there was no significant improvement in treated mdx mice.
    2 context sentences
    Summary · context
    Female wild type (C57BL10/ScSnJ) and mdx mice, 8-10 weeks old, were treated with 150 microg of Tbeta4 twice a week for 6 months.
    Summary · context
    To promote muscle pathology, mice were exercised for 30 minutes twice a week.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.